Background
Chronic corticosteroid use significantly impairs wound healing through multiple mechanisms: suppressed fibroblast proliferation, reduced collagen synthesis, inhibited angiogenesis, and blunted inflammatory resolution. This creates a clinically important problem — patients requiring corticosteroids for inflammatory conditions are simultaneously impaired in their tissue repair capacity.
BPC 157 (Body Protection Compound 157, pentadecapeptide Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) had previously shown accelerated healing in normal animal models. Pevec and colleagues investigated whether BPC 157 could specifically counteract corticosteroid-induced healing impairment — a condition with very few effective interventions.
Methods
Rat gastrocnemius muscle was injured by standardized crush injury. Animals were then randomized to:
- Corticosteroid alone (methylprednisolone 1 mg/kg/day)
- BPC 157 alone (10 µg/kg, daily IP)
- Corticosteroid + BPC 157 combined
- Saline control (normal healing)
Healing assessed at days 7, 14, and 21 by:
- Tensiometry (tensile breaking strength)
- Histomorphometry (fibroblast density, collagen fiber organization)
- Macroscopic healing score
- Immunohistochemistry: VEGF, TGF-β1 expression
Key Findings
Tensile Strength Recovery:
| Group | Day 21 Tensile Strength (% of normal) |
|---|---|
| Normal healing (control) | 78% |
| Methylprednisolone alone | 48% |
| BPC 157 alone | 89% |
| Methylprednisolone + BPC 157 | 74% |
- BPC 157 alone outperformed even normal healing
- BPC 157 combined with methylprednisolone restored healing to near-normal levels despite ongoing corticosteroid impairment
Histological Findings:
- Methylprednisolone group: sparse, disorganized collagen fibers; reduced fibroblast density; poor vascular ingrowth
- BPC 157 + methylprednisolone: organized parallel collagen fiber architecture; restored fibroblast density comparable to normal healing
- Collagen fiber density score: 2.1 (methpred alone) vs. 4.2 (BPC157 + methpred) vs. 4.5 (normal healing); scale 1–5
Angiogenesis (VEGF):
- VEGF expression at day 7: Methylprednisolone significantly suppressed VEGF (−44% vs. saline control)
- BPC 157 + methylprednisolone: VEGF restored to 91% of saline control levels
- New capillary formation confirmed histologically in BPC 157 groups
TGF-β1 Expression:
- BPC 157 upregulated TGF-β1 in healing tissue — the key cytokine for fibroblast recruitment and collagen deposition
- The TGF-β1 upregulation was maintained even in the presence of corticosteroids, suggesting BPC 157 acts through a steroid-independent pathway
Mechanistic Significance
BPC 157’s rescue of corticosteroid-impaired healing implicates several pathways:
- VEGF-independent angiogenesis: BPC 157 may promote vessel formation through Egr-1/VEGFR2 and FAK-paxillin pathways that bypass corticosteroid inhibition
- Nitric oxide system: BPC 157 modulates NO production in healing tissue — NO is required for vascular endothelial function and fibroblast activity
- Tendon/muscle fibroblast activation: Direct stimulation of fibroblasts via BPC 157-sensitive receptor pathways, independent of glucocorticoid receptor signaling
- Inflammatory resolution: BPC 157 promotes the transition from inflammatory to proliferative healing phase, counteracting corticosteroids’ excessive suppression of early healing inflammation
Clinical Significance
- Steroid-dependent patients: Patients on long-term corticosteroids (autoimmune disease, transplant recipients, asthma) who sustain muscle injuries represent a high-risk group with limited healing options — BPC 157 co-administration may restore normal healing capacity
- Athletic injury in steroid-using athletes: Though illicitly, many performance-oriented athletes use both corticosteroids for inflammation and BPC 157 for recovery — this study provides mechanistic support for the combination
- Post-surgical healing: Corticosteroid-dependent patients undergoing surgery face impaired incisional healing; BPC 157 as an adjunct is mechanistically supported
- GI mucosal healing: BPC 157’s original characterization was for gastrointestinal healing; corticosteroid-impaired gut healing (e.g., in IBD patients) represents another potential application
Limitations
- Rat model with standardized crush injury — clinical muscle injuries are heterogeneous in mechanism, severity, and patient biology
- Intraperitoneal administration in rats does not reflect common human routes (oral, subcutaneous)
- Methylprednisolone dose used (1 mg/kg/day) is equivalent to a high human corticosteroid dose — translation to lower chronic doses may show different results
- No human trials of BPC 157 for corticosteroid-impaired healing have been published